Edition:
United States

Retrophin Inc (RTRX.O)

RTRX.O on Consolidated Issue listed on NASDAQ Global Market

28.62USD
25 Sep 2018
Change (% chg)

$0.87 (+3.14%)
Prev Close
$27.75
Open
$27.81
Day's High
$28.71
Day's Low
$27.39
Volume
307,005
Avg. Vol
369,868
52-wk High
$33.00
52-wk Low
$20.09

Chart for

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $1,121.84
Shares Outstanding(Mil.): 40.43
Dividend: --
Yield (%): --

Financials

  RTRX.O Industry Sector
P/E (TTM): -- 109.17 32.55
EPS (TTM): -1.89 -- --
ROI: -18.43 1.47 12.80
ROE: -25.73 0.22 14.92

BRIEF-Retrophin Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S

May 01 2018

BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis

* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:

Apr 03 2018

Earnings vs. Estimates